Cargando…

NK Cells in the Treatment of Hematological Malignancies

Natural killer (NK) cells have the innate ability to kill cancer cells, however, tumor cells may acquire the capability of evading the immune response, thereby leading to malignancies. Restoring or potentiation of this natural antitumor activity of NK cells has become a relevant therapeutic approach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez-Rodriguez, Ana P, Villa-Álvarez, Mónica, Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, Gonzalez, Segundo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832953/ https://www.ncbi.nlm.nih.gov/pubmed/31569769 http://dx.doi.org/10.3390/jcm8101557

Ejemplares similares

NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
por: Villa-Álvarez, Mónica, et al.
Publicado: (2018)

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Immunosurveillance of cancer cell stress
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Chemo-Immunotherapy: A New Trend in Cancer Treatment
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression
por: Gonzalez-Rodriguez, Ana P., et al.
Publicado: (2020)

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma
por: Lorenzo‐Herrero, Seila, et al.
Publicado: (2022)

NK Cell-Based Immunotherapy for Hematological Malignancies
por: Sivori, Simona, et al.
Publicado: (2019)

Monitoring NK cell activity in patients with hematological malignancies
por: Viel, Sébastien, et al.
Publicado: (2013)

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
por: Cantoni, Claudia, et al.
Publicado: (2016)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
por: Shimizu, Kanako, et al.
Publicado: (2020)

Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
por: Tumino, Nicola, et al.
Publicado: (2021)

Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
por: Huergo-Zapico, Leticia, et al.
Publicado: (2014)

Abstract 2 Development of CAR-NK Cell Therapy for Hematologic Malignancies
por: Stoltzman, Carrie, et al.
Publicado: (2022)

Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications
por: Farnault, Laure, et al.
Publicado: (2012)

A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies
por: Kim, Hun Sik
Publicado: (2015)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies
por: Ramos-Mejia, Veronica, et al.
Publicado: (2022)

SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
por: Andrades, Alvaro, et al.
Publicado: (2023)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

The treatment of hematologic malignancies in pregnancy
por: Vandenbriele, C., et al.
Publicado: (2010)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors
por: Velichinskii, Rodion A., et al.
Publicado: (2021)

Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure
por: Uribe-Herranz, Mireia, et al.
Publicado: (2021)

Lectin-Like Transcript 1 (LLT1) Checkpoint: A Novel Independent Prognostic Factor in HPV-Negative Oropharyngeal Squamous Cell Carcinoma
por: Sanchez-Canteli, Mario, et al.
Publicado: (2020)

Bispecific Antibodies in the Treatment of Hematologic Malignancies
por: Duell, Johannes, et al.
Publicado: (2019)

Nanomedicine approaches for treatment of hematologic and oncologic malignancies
por: Nteli, Polyxeni, et al.
Publicado: (2022)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_l8aftfs33mtabj2dmj9ub4u4lq